Congress trades
Alexion Pharmaceuticals, Inc. (ALXN)
About Alexion Pharmaceuticals, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Ludwig Hantson
- Employees
- 3,837
- Listed since
- Feb 1, 1996
- Market value
- -
- Price to earnings
- 66.4
- Earnings per share
- $2.75
- Dividend yield
- -
Earnings
6 reported quarters · next on Jul 29, 2021| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q1 FY2021reported Apr 30, 2021 | $3.52 | $3.16 | $1.6B | $1.6B | EPS beatRevenue beat |
| Q4 FY2020reported Feb 4, 2021 | $2.96 | $2.56 | $1.6B | $1.5B | EPS beatRevenue beat |
| Q3 FY2020reported Oct 29, 2020 | $3.24 | $2.60 | $1.6B | $1.3B | EPS beatRevenue beat |
| Q2 FY2020reported Jul 30, 2020 | $3.11 | $2.59 | $1.4B | $1.2B | EPS beatRevenue beat |
| Q1 FY2020reported May 6, 2020 | $3.22 | $2.71 | $1.4B | $1.2B | EPS beatRevenue beat |
| Q4 FY2019reported Jan 30, 2020 | $2.71 | $2.60 | $1.4B | $1.3B | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in ALXN
20 disclosures of 106 on record · median 29d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $15,001 - $50,000 | +18.7%S&P +17.4% · vs S&P 500 +1.3% | Dec 22, 2020 | Jan 11, 2021 | 20d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $50,001 - $100,000 | +17.9%S&P +16.7% · vs S&P 500 +1.2% | Dec 21, 2020 | Jan 11, 2021 | 21d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +56.0%S&P +28.4% · vs S&P 500 +27.6% | Nov 3, 2020 | Dec 16, 2020 | 43d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +68.1%S&P +35.2% · vs S&P 500 +32.9% | Jul 14, 2020 | Aug 19, 2020 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +70.5%S&P +37.0% · vs S&P 500 +33.5% | Jul 13, 2020 | Aug 19, 2020 | 37d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +121.2%S&P +80.0% · vs S&P 500 +41.2% | Mar 18, 2020 | Apr 16, 2020 | 29d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | +84.3%S&P +33.7% · vs S&P 500 +50.6% | Feb 24, 2020 | Mar 10, 2020 | 15d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +84.3%S&P +33.7% · vs S&P 500 +50.6% | Feb 24, 2020 | Mar 10, 2020 | 15d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | +81.5%S&P +29.8% · vs S&P 500 +51.7% | Feb 7, 2020 | Mar 10, 2020 | 32d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +78.1%S&P +28.6% · vs S&P 500 +49.5% | Feb 11, 2020 | Mar 9, 2020 | 27d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +68.1%S&P +32.9% · vs S&P 500 +35.2% | Jan 8, 2020 | Feb 10, 2020 | 33d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +74.1%S&P +44.3% · vs S&P 500 +29.8% | Oct 15, 2019 | Nov 12, 2019 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +81.2%S&P +43.8% · vs S&P 500 +37.4% | Oct 21, 2019 | Nov 12, 2019 | 22d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +68.1%S&P +43.7% · vs S&P 500 +24.4% | Sep 16, 2019 | Oct 16, 2019 | 30d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +67.9%S&P +49.8% · vs S&P 500 +18.1% | Aug 12, 2019 | Sep 11, 2019 | 30d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +69.5%S&P +52.1% · vs S&P 500 +17.5% | Aug 14, 2019 | Sep 11, 2019 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +45.7%S&P +45.3% · vs S&P 500 +0.3% | Jul 8, 2019 | Aug 6, 2019 | 29d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +60.0%S&P +57.2% · vs S&P 500 +2.9% | Jun 3, 2019 | Jul 11, 2019 | 38d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +46.0%S&P +54.0% · vs S&P 500 -7.9% | May 28, 2019 | Jun 11, 2019 | 14d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +37.9%S&P +47.3% · vs S&P 500 -9.5% | Apr 23, 2019 | May 10, 2019 | 17d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 6, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded ALXN?
Gilbert Ray Cisneros, Jr., Ro Khanna disclosed ALXN transactions in the filings shown here.
How quickly are ALXN trades disclosed?
Congressional disclosures took a median of 29 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.